Human-Centered AI for
Drug Discovery
Combines AI with human-relevant biology to accelerate drug discovery—grounded in ethics, usability, and real-world impact.
About Us
Empowered by AI,
Designed for Humanity.
AI x HUMAN-RELEVANT BIOLOGY
Human-Centered AI for
AI-POWERED
Microphysiological Platform
Organ-on-chip + AI agents to deliver faster, more reliable preclinical insights.
3RS PRINCIPLEReplace, Reduce,
Replace, Reduce,
and Refine
Driven by the 3Rs, our global team is redefining drug development with scalable, animal-free solutions.
MEET THEFOUNDER
“
No Animals, No Delays, Just Human Data'
is the future we envision.'No Animals, No Delays,
Just Human Data'
is the future we envision.
Dr. Guan-Yu Chen is the Founder and CEO of Anivance AI, a biotechnology company building physical AI infrastructure for human biology through organ-on-chip systems, laboratory automation, and AI-driven biomedical analysis.
Spun out from National Yang Ming Chiao Tung University (NYCU), the company builds on more than a decade of Dr. Chen's research in organ-on-chip technologies and bioengineering.
50+Publications
30+Research Programs
25+International Patents
Selected Honors
- Lush Prize Asia Young Researcher Award
- Ten Outstanding Young Persons Award (Taiwan)
- Moderna Taiwan mRNA Innovation Award
Awards &Recognition
LUSH Prize – Young Researcher Award (Asia)
Berlin, Germany | 2018
